AZD-1390
- Generic Name
- AZD-1390
AstraZeneca's AZD1390 Enters GBM AGILE Trial for Newly Diagnosed Glioblastoma Patients
• The Global Coalition for Adaptive Research (GCAR) has activated AstraZeneca's AZD1390 as the seventh investigational arm in the GBM AGILE platform trial for newly diagnosed glioblastoma patients.
• AZD1390, a brain-penetrant ATM kinase inhibitor, has shown promise in enhancing radiation therapy effectiveness by blocking DNA repair mechanisms in tumor cells, with Phase I data demonstrating manageable toxicity.
• The registrational-intent Phase 2/3 adaptive platform trial has already screened over 2,300 patients across six countries since 2019, with results potentially supporting future FDA approval applications.
AstraZeneca's AZD1390 to be Evaluated in GBM AGILE Trial for Glioblastoma
• AstraZeneca's AZD1390 will be evaluated in the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial, a global adaptive platform.
• The trial, designed with response adaptive randomization and a Phase II/III structure, aims to accelerate the identification of effective glioblastoma therapies.
• AZD1390 arm will focus on newly diagnosed glioblastoma patients, with recruitment anticipated to commence in the second quarter of next year.
• GBM AGILE, operating under a master protocol, allows concurrent evaluation of multiple treatments against a common control arm.
AZD1390 to be Evaluated in GBM AGILE Trial for Newly Diagnosed Glioblastoma
• AstraZeneca's AZD1390, a brain-penetrant ATM kinase inhibitor, will be evaluated in the GBM AGILE trial for newly diagnosed glioblastoma patients.
• GBM AGILE is an adaptive platform trial designed to expedite the identification of effective therapies for glioblastoma, an aggressive brain cancer.
• AZD1390 has shown encouraging preliminary efficacy in recurrent glioblastoma and potential as a radiosensitizer in earlier studies.
• Patient recruitment for the AZD1390 arm of the GBM AGILE trial is expected to commence by Q2 2025.
AZD1390, an ATM Kinase Inhibitor, to Be Evaluated in GBM AGILE Trial for Glioblastoma
• AstraZeneca's AZD1390, a novel ATM kinase inhibitor, will be evaluated in the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial.
• AZD1390 will be assessed as a treatment for newly diagnosed glioblastoma, with patient recruitment slated to commence in early 2025.
• GBM AGILE is an international adaptive platform trial designed to evaluate multiple therapies simultaneously against a shared control arm.
• AZD1390 has demonstrated a manageable safety profile and preliminary efficacy in combination with radiotherapy in a phase I trial for glioblastoma.
AZD1390 to be Evaluated in GBM AGILE Trial for Newly Diagnosed Glioblastoma
• AstraZeneca's AZD1390, a brain-penetrant ATM kinase inhibitor, will be evaluated in the GBM AGILE trial for newly diagnosed glioblastoma patients.
• The GBM AGILE trial, an adaptive platform trial, aims to identify effective therapies for glioblastoma, the most aggressive form of primary brain cancer.
• AZD1390 has shown encouraging preliminary efficacy in recurrent glioblastoma patients and potential as a radiosensitizer in earlier studies.
• Patient recruitment for the AZD1390 arm of the GBM AGILE trial is expected to commence in Q2 2025.
AZD1390 to be Evaluated in GBM AGILE Trial for Glioblastoma
• AstraZeneca's AZD1390, a brain-penetrant ATM kinase inhibitor, will be evaluated in the GBM AGILE trial for newly diagnosed glioblastoma patients.
• GBM AGILE is an adaptive platform trial designed to expedite the identification of effective therapies for glioblastoma, an aggressive brain cancer.
• AZD1390 has shown preliminary efficacy and a manageable safety profile in combination with radiotherapy in a Phase I trial for glioblastoma patients.
• Recruitment for the AZD1390 arm of the GBM AGILE trial is expected to begin in Q2 2025, with the goal of improving outcomes for glioblastoma patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath